(Q36563576)

14 August 2017

title

The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta (English)

1 reference

14 August 2017

main subject

anti-retroviral agent

0 references

author name string

Gingues S

series ordinal

1

1 reference

14 August 2017

Gill MJ

series ordinal

2

1 reference

14 August 2017

publication date

1 September 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

6

1 reference

14 August 2017

page(s)

369-377

1 reference

Antitumour effects of antiretroviral therapy

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

Advances in the pathobiology and treatment of Kaposi sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

AIDS-associated cancer in developing nations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

Starting highly active antiretroviral therapy: why, when and response to HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

Anogenital neoplasia in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active an

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

Pathogenesis of HIV-associated non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

Kaposi's sarcoma: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

HIV protease inhibitors as new treatment options for Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

Clinical presentations and standard therapy of AIDS-associated Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

Cancer incidence in New York State acquired immunodeficiency syndrome patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

Outcome in patients with non-hodgkin lymphoma and with or without human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

A recurrent pattern of chromosomal aberrations and immunophenotypic appearance defines anal squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

Trends in AIDS-Defining and Non--AIDS-Defining Malignancies among HIV-Infected Patients: 1989-2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2006.00395.X

10.1111/J.1468-1293.2006.00395.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference